The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Indications for Early Aspirin Use in Acute Ischemic Stroke: A Combined Analysis of 40 000 Randomized Patients From the Chinese Acute Stroke Trial and the International Stroke Trial
Abstract
Background and Purpose —Long-term daily aspirin is of benefit in the years after ischemic stroke, and 2 large randomized trials (the Chinese Acute Stroke Trial [CAST] and the International Stroke Trial [IST]), with 20 000 patients in each, have shown that starting daily aspirin promptly in patients with suspected acute ischemic stroke also reduces the immediate risk of further stroke or death in hospital and the overall risk of death or dependency. However, some uncertainty remains about the effects of early aspirin in particular categories of patient with acute stroke. Methods —To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups. This represents 99% of the worldwide evidence from randomized trials. Results —There was a highly significant reduction of 7 per 1000 (SD 1) in recurrent ischemic stroke (320 [1.6%] aspirin versus 457 [2.3%] control, 2 P <0.000001) and a less clearly significant reduction of 4 (SD 2) per 1000 in death without further stroke (5.0% versus 5.4%, 2 P =0.05). Against these benefits, there was an increase of 2 (SD 1) per 1000 in hemorrhagic stroke or hemorrhagic transformation of the original infarct (1.0% versus 0.8%, 2 P =0.07) and no apparent effect on further stroke of unknown cause (0.9% versus 0.9%). In total, therefore, there was a net decrease of 9 (SD 3) per 1000 in the overall risk of further stroke or death in hospital (8.2% versus 9.1%, 2 P =0.001). For the reduction of one third in recurrent ischemic stroke, subgroup-specific analyses found no significant heterogeneity of the proportional benefit of aspirin (χ 2 18 =20.9, NS), even though the overall treatment effect (χ 2 1 =24.8, 2 P <0.000001) was sufficiently large for such subgroup analyses to be statistically informative. The absolute risk among control patients was similar in all 28 subgroups, so the absolute reduction of ≈7 per 1000 in recurrent ischemic stroke does not differ substantially with respect to age, sex, level of consciousness, atrial fibrillation, CT findings, blood pressure, stroke subtype, or concomitant heparin use. There was no good evidence that the apparent decrease of ≈4 per 1000 in death without further stroke was reversed in any subgroup or that in any subgroup the increase in hemorrhagic stroke was much larger than the overall average of ≈2 per 1000. Finally, there was no significant heterogeneity between the reductions in the composite outcome of any further stroke or death (χ 2 18 =16.5, NS). Among the 9000 patients (22%) randomized without a prior CT scan, aspirin appeared to be of net benefit with no unusual excess of hemorrhagic stroke; moreover, even among the 800 (2%) who had inadvertently been randomized after a hemorrhagic stroke, there was no evidence of net hazard (further stroke or death, 63 aspirin versus 67 control). Conclusions —Early aspirin is of benefit for a wide range of patients, and its prompt use should be routinely considered for all patients with suspected acute ischemic stroke, mainly to reduce the risk of early recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Self-citationAntiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
Chen, Z.-M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04010-5 · Cited by 1,232
Self-citationMulticentre Acute Stroke Trial—Italy (MAST-I) Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92049-8 · Cited by 633
Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials
He, J., Whelton, P. K., Vu, B., & Klag, M. J. (1998) · JAMA · doi:10.1001/jama.280.22.1930 · Cited by 521
Percutaneous implantation of autologous vein graft stent for treatment of coronary artery disease
Stefanadis, C., & TOUTOUZAS, P. K. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91066-2 · Cited by 143
Cerebrovascular disease in the People's Republic of China: Epidemiologic and clinical features
Li, S., Schoenberg, B. S., Wang, C., Cheng, X.-M., Bolis, C. L., & Wang, K. (1985) · Neurology · doi:10.1212/wnl.35.12.1708 · Cited by 141
Incidence of stroke in Oxfordshire: first year's experience of a community stroke register.
(1983) · BMJ · doi:10.1136/bmj.287.6394.713 · Cited by 100
Stroke treatment: time is brain
Hill, M. D., & Hachinski, V. (1998) · The Lancet · doi:10.1016/s0140-6736(98)90088-5 · Cited by 56
Aspirin or heparin immediately after a stroke?
Bousser, M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)22022-2 · Cited by 45
Antiplatelet Therapy in Acute Cerebral Ischemia
Bednar, M. M., & Gross, C. E. (1999) · Stroke · doi:10.1161/01.str.30.4.887 · Cited by 44
Interpretation of IST and CAST stroke trials
Barer, D. H. (1997) · The Lancet · doi:10.1016/s0140-6736(97)26032-0 · Cited by 16
Interpretation of IST and CAST stroke trials
Sandercock, P. A., & Counsell, C. E. (1997) · The Lancet · doi:10.1016/s0140-6736(05)64169-4 · Cited by 2
Self-citation
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Metadata
- Authors
- Chen, Z., Sandercock, P., Pan, H., Counsell, C., Collins, R., Liu, L., Xie, J., Warlow, C., & Peto, R.
- Venue
- Stroke
- Published
- 2000-06
- Volume
- 31
- Issue
- 6
- Pages
- 1240-1249
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W1971442835
- Cited by
- 599
- References
- 16
- FWCI
- 17.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.